Dr. Alter Discusses Provenge MOA and Tolerability

Robert S. Alter, MD
Published Online: Friday, December 2, 2011
Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading